Prothena Corporation (PRTA) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Prothena Corporation (PRTA) overview

Prothena Corporation (PRTA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 9.7m and operating profit of USD -215m; the year-end share price was 9.55 USD and market capitalisation was USD 514m. Prothena Corporation is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Prothena Corporation's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 280mFY 2025
Share price9.55 USDFY 2025 year end
RevenueUSD 9.7mFY 2025
Operating profitUSD -215mFY 2025
Net earningsUSD -244mFY 2025
Market capitalisationUSD 514mFY 2025 year end

About Prothena Corporation

Prothena is a clinical-stage biotechnology company developing therapies for diseases associated with protein dysregulation, including neurodegenerative and peripheral amyloid diseases. Its wholly owned and partnered programs address conditions such as Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, and ALS. The company also develops CYTOPE technology for targeting intracellular disease pathways in the brain and periphery.

Generate the Prothena Corporation report

Prothena Corporation is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Prothena Corporation and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Prothena Corporation

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.